Evidence map›Paper›PMID 36680753›Full record

ArticleTissue engineering. Part C, Methods2023

Safety of Allogeneic Mesenchymal Stem Cell Seeding of NeuraGen Nerve Guides in a Rabbit Model.

Meiwand Bedar, Andre J van Wijnen, Alexander Y Shin

Open access · greenAbstract read
In one paragraph

Article in Tissue engineering. Part C, Methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Meiwand BedarDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Andre J van WijnenDepartment of Biochemistry, University of Vermont College of Medicine, Burlington, Vermont, USA.
Alexander Y ShinDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.
Mayo Clinic · USUniversity of Vermont · US

Funding

Bridging the gap: Angiogenesis and stem cell seeding of processed nerve allograftR01NS102360 · NINDS · MAYO CLINIC ROCHESTER · PI SHIN, ALEXANDER Y. · 2018 to 2022
$1.7M
NINDS NIH HHS R01 NS102360
6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) stimulate nerve and tissue regeneration and are primed for clinical translation. Application of autologous MSCs is limited by requirements for expedient harvesting procedures, proliferative expansion to increase number of cells, and reduced regenerative potential due to aging or pathological conditions. Because MSCs are immune privileged, allogeneic MSCs may serve as "off-the-shelf" cell-based reconstructive treatments to support nerve repair. Therefore, we examined the safety and immune response parameters of allogeneic MSCs seeded on NeuraGen

Indexed as

Hematopoietic Stem Cell TransplantationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsRabbitsWound Healingallogeneic mesenchymal stem cellscell transplantationcollagen nerve conduitnerve graft substituterabbit model

Identifiers

PMID36680753
PMCPMC10162580
OpenAlexW4317666718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.